Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous PBSC Transplantation with Retroviral Marking for Lymphoma
NCT00005998Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2000
- Primary completion
- Mar 2003
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
01
Overview
Phase 2, open-label, single-arm trial of Retrovirus vector LN in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), sponsored by Masonic Cancer Center. Primary endpoints: Yield of hematopoietic progenitors in peripheral blood stem cells, Transduction efficiency of early and late engrafting hematopoietic stem cells at 24 months and 1 more. Planned start Jan 2000; status: withdrawn.
02
Drugs
Retrovirus vector LN
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00005998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005998.